Status:
NOT_YET_RECRUITING
The Clinical Trial of Electro-thumbtack Needle on Live Birth Rate in Patients With Ovarian Reserve Dysfunction (DOR)
Lead Sponsor:
Huazhong University of Science and Technology
Conditions:
Diminished Ovarian Reserve (DOR)
Eligibility:
FEMALE
18-40 years
Phase:
NA
Brief Summary
This study will include 246 patients with ovarian reserve dysfunction (DOR), who will be randomly divided into a treatment group and a control group, with 123 patients in each group. The treatment gro...
Eligibility Criteria
Inclusion
- The age range is 18-40 years old;
- Meets the diagnostic criteria for DOR as follows: ① AMH\<1.1 ng/ml; ② 10 U/L \< FSH \< 25U/L or FSH/LH \> 3.6; ③ The total number of follicles (AFC) in both basal sinuses is less than 7. If any two of the above criteria (①②③) are met, it can be diagnosed as DOR.
- At least one side of the patient's fallopian tube is unobstructed;
- The semen routine examination of the patient's spouse is normal;
- Voluntarily sign the informed consent form.
Exclusion
- Chromosomal or genetic abnormalities in either the female or male partner;
- Women with blocked fallopian tubes on both sides;
- Have a history of ovarian surgery, such as ovarian teratoma or ovarian chocolate cyst surgery;
- The female party suffers from uncorrected endocrine disorders such as simple hyperthyroidism or hypothyroidism, hyperprolactinemia, and pancreatic islet dysfunction;
- Hormone resistance, diabetes, adrenal diseases, etc;
- The woman has a clearly diagnosed autoimmune disease such as systemic lupus erythematosus, rheumatoid arthritis;
- Antiphospholipid syndrome, Sjogren's syndrome, Hashimoto's thyroiditis, etc;
- The female or male partner has a history of malignant tumors and has received treatment with radiotherapy and chemotherapy;
- The woman has received acupuncture and moxibustion or press acupuncture treatment in recent 3 months;
- Those who take traditional Chinese medicine decoctions or granules during treatment;
- Men with abnormal semen examination;
- Clear diagnosis of moderate or severe adenomyosis;
- Clearly diagnose uterine fibroids with a diameter greater than 5cm;
- I do not agree to sign the informed consent form for this study.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2029
Estimated Enrollment :
368 Patients enrolled
Trial Details
Trial ID
NCT07142187
Start Date
October 1 2025
End Date
October 30 2029
Last Update
August 26 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.